肿瘤学和免疫肿瘤学剂量探索中的挑战与机遇 - Suppr

Suppr

超能文献

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

作者信息

Ji Yan, Jin Jin Y, Hyman David M, Kim Geoffrey, Suri Ajit

机构信息

PK Sciences, Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA.

Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.

出版信息

Clin Transl Sci. 2018 Jul;11(4):345-351. doi: 10.1111/cts.12540. Epub 2018 Feb 1.

DOI:10.1111/cts.12540

PMID:29392871

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6039198/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d23/6039198/5d7b397f058e/CTS-11-345-g001.jpg

相似文献

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

Clin Transl Sci. 2018 Jul;11(4):345-351. doi: 10.1111/cts.12540. Epub 2018 Feb 1.

Making precision oncology the standard of care.

Lancet Oncol. 2017 Jul;18(7):835. doi: 10.1016/S1470-2045(17)30474-6.

What was wrong and might now go right with clinical trials for lupus?

Curr Rheumatol Rep. 2009 Aug;11(4):235-7. doi: 10.1007/s11926-009-0044-y.

Development of rational drug combinations with investigational targeted agents.

Oncologist. 2010;15(5):496-9. doi: 10.1634/theoncologist.2009-0262.

Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.

Clin Trials. 2024 Jun;21(3):267-272. doi: 10.1177/17407745241234652. Epub 2024 Apr 3.

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Ann Oncol. 2018 Aug 1;29(8):1727-1740. doi: 10.1093/annonc/mdy225.

Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.

Clin Pharmacol Ther. 2019 Jun;105(6):1303-1320. doi: 10.1002/cpt.1352. Epub 2019 Feb 25.

A Tale of Two Trials.

Arthritis Rheumatol. 2020 Aug;72(8):1256-1257. doi: 10.1002/art.41261. Epub 2020 Jun 19.

Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.

Clin Pharmacol Ther. 2019 Mar;105(3):582-597. doi: 10.1002/cpt.1123. Epub 2018 Sep 12.

First-in-man and first-of-class-in-man clinical trials in oncology.

Int J Clin Pharmacol Ther. 2009 Jan;47(1):68-70. doi: 10.5414/cpp47068.

引用本文的文献

Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.

Clin Transl Sci. 2025 Jul;18(7):e70287. doi: 10.1111/cts.70287.

An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.

Cancer Chemother Pharmacol. 2025 Mar 28;95(1):48. doi: 10.1007/s00280-025-04775-8.

A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials.

Pharm Stat. 2025 Mar-Apr;24(2):e2451. doi: 10.1002/pst.2451. Epub 2024 Nov 10.

Moving the needle for oncology dose optimization: A call for action.

Clin Transl Sci. 2024 Jun;17(6):e13859. doi: 10.1111/cts.13859.

Deep Learning Insights into the Dynamic Effects of Photodynamic Therapy on Cancer Cells.

Pharmaceutics. 2024 May 16;16(5):673. doi: 10.3390/pharmaceutics16050673.

Moving the needle for oncology dose optimization: A call for action.

CPT Pharmacometrics Syst Pharmacol. 2024 Jun;13(6):909-918. doi: 10.1002/psp4.13157. Epub 2024 May 22.

Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.

Breast Cancer Res. 2024 May 22;26(1):81. doi: 10.1186/s13058-024-01832-7.

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.

Clin Transl Sci. 2024 Mar;17(3):e13769. doi: 10.1111/cts.13769.

Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy.

Cancer Chemother Pharmacol. 2024 Apr;93(4):273-293. doi: 10.1007/s00280-024-04643-x. Epub 2024 Mar 2.

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

Leukemia. 2024 Mar;38(3):475-481. doi: 10.1038/s41375-024-02159-0. Epub 2024 Jan 29.

本文引用的文献

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1.

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.

Clin Pharmacol Ther. 2017 May;101(5):657-666. doi: 10.1002/cpt.656. Epub 2017 Mar 22.

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.

Clin Pharmacol Ther. 2017 Aug;102(2):305-312. doi: 10.1002/cpt.587. Epub 2017 Jun 9.

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.

J Immunother Cancer. 2016 Nov 15;4:72. doi: 10.1186/s40425-016-0177-2. eCollection 2016.

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.

Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.

Clin Pharmacol Ther. 2017 Jan;101(1):99-113. doi: 10.1002/cpt.544. Epub 2016 Nov 25.

An FDA oncology analysis of immune activating products and first-in-human dose selection.

Regul Toxicol Pharmacol. 2016 Nov;81:448-456. doi: 10.1016/j.yrtph.2016.10.002. Epub 2016 Oct 13.

Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.

Clin Cancer Res. 2016 Jun 1;22(11):2630-8. doi: 10.1158/1078-0432.CCR-15-2646.

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.

Clin Cancer Res. 2016 Jun 1;22(11):2623-9. doi: 10.1158/1078-0432.CCR-15-2644.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验